Arrowhead Pharmaceuticals, INC. (ARWR) — 10-Q Filings

All 10-Q filings from Arrowhead Pharmaceuticals, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Arrowhead's Q3 Loss Widens on Higher R&D, Revenue Declines — Aug 7, 2025 Risk: high
Arrowhead Pharmaceuticals reported a net loss of $50.3 million for the three months ended June 30, 2025, a significant increase from the net loss of $39.8 milli
Arrowhead Pharmaceuticals Files 10-Q for Q2 2025 — May 12, 2025 Risk: medium
Arrowhead Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its busi
Arrowhead Pharma Files Q4 2024 Report — Feb 10, 2025 Risk: low
Arrowhead Pharmaceuticals, Inc. filed its quarterly report for the period ended December 31, 2024. The company is registered in Delaware and trades on The Nasda
Arrowhead Pharmaceuticals Files Q3 2024 10-Q — Aug 8, 2024 Risk: medium
Arrowhead Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its busin
Arrowhead Pharma Files Q2 2024 10-Q — May 9, 2024 Risk: medium
Arrowhead Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported its financial results and provided updates on its busi
Arrowhead Pharmaceuticals, Inc. Files 10-Q for Period Ending December 31, 2023 — Feb 6, 2024 Risk: medium
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed a Quarterly Report (10-Q) with the SEC on February 6, 2024. Arrowhead Pharmaceuticals, Inc. filed a 10-Q report for

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX